

## **Prior authorization requirements for Part B drug: Trelstar (triptorelin)**

On **August 1, 2018**, the Amerigroup Community Care prior authorization (PA) requirement will change for Part B injectable/infusible drug Trelstar (triptorelin) covered by Amerigroup. Federal and state law, as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions, take precedence over these precertification rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims.

PA requirements will be added to the following Part B drug:

- Trelstar (triptorelin): for the palliative treatment of advanced prostate cancer and the treatment of central precocious puberty J3315

To request PA, you may use one of the following methods:

- Phone: 1-844-799-4129
- Fax: 1-844-765-5160
- Interactive Care Reviewer: <https://www.Availity.com>

Not all PA requirements are listed here. Detailed PA requirements are available to contracted providers by accessing the provider self-service tool through the Availity Portal at <https://providers.amerigroup.com/NJ> > **Login**. Contracted and noncontracted providers who are unable to access Availity may call our Provider Services at 1-844-799-4129 for assistance with PA requirements.